Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
ZymoGenetics, Inc.
ZymoGenetics Announces Publication of Five IL-21 ASCO Abstracts
June 3rd, 2008
ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that results from Interleukin 21 (IL-21) studies will be presented or published at the American Society of Clinical Oncology (ASCO) 2008 annual meeting. Renal cell cancer is the lead indication for IL-21, and previously, ZymoGenetics presented interim results from a Phase 1 trial combining IL-21 with Nexavar(R) (sorafenib) tablets. Additional data from Phase 1 published in the ASCO proceedings confirm that the combination is well-tolerated and shows anti-tumor activity. ZymoGenetics also reported positive results from the cohort expansion portion of a Phase 1 study with IL-21 and Rituxan(R) in relapsed/refractory indolent lymphoma. Results from...
Source: Cancer Weekly (2008-06-03)
|
